NEW YORK, Sept. 05, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Dr. Reddy’s Laboratories Ltd. ("Dr. Reddy’s") (NYSE:RDY) between June 17, 2015 and August 10, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/plsra-c/dr-reddys-laboratories-ltd?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India.
If you suffered a loss in Dr. Reddy’s you have until October 24, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 



